Phase II Trial of Belumosudil and Rituximab for the Primary Treatment of Extensive Chronic Graft-versus-host Disease
Latest Information Update: 18 Mar 2024
At a glance
- Drugs Belumosudil (Primary) ; Rituximab (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
Most Recent Events
- 11 Mar 2024 Status changed from not yet recruiting to recruiting.
- 26 Sep 2023 New trial record